Takeda's Phase 3 ADVANCE-CIDP 3 trial of HYQVIA for CIDP patients shows favorable long-term safety, tolerability, and low relapse rate.
Takeda Pharmaceutical announces promising long-term results from its Phase 3 ADVANCE-CIDP 3 clinical trial of HYQVIA for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients. This long-term extension study shows favorable safety, tolerability, and low relapse rate, supporting HYQVIA as a maintenance therapy for CIDP. The ADVANCE-CIDP 3 trial is the longest study in CIDP clinical trials.
June 18, 2024
4 Articles